{"entity":{"id":"nct06102161","kind":"trial","name":"Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)","aka":[],"tldr":"A phase 3 trial in lung cancer, run by Fudan University, not yet recruiting.","summary":"Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020) is a phase 3, interventional study registered as NCT06102161 by Fudan University, with a registry enrolment figure of 286 participants, started 2023-11 and due to reach its primary completion in 2025-11. Interventions recorded: Wedge resection. Conditions listed: Lung Cancer; Wedge Resection; Ground-glass Opacity. Primary outcome: 5-year overall survival. Lung eligibility wording from the registry: \"Not receiving lung cancer surgery before;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06102161","url":"https://clinicaltrials.gov/study/NCT06102161"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06102161","phase":"3","setting":"Wedge Resection for Ground-glass Opacity-featured Lung Cancer With Size Less Than 2cm and Consolidation-to-tumor Ratio Between 0.25 to 0.5: a Single-arm, Multi-center, Prospective, Confirmatory Phase III Trial","sponsor":"Fudan University","enrolled":286,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06102161/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}